SPEX - AIkido Pharma Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.6300
-0.3600 (-18.09%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.9900
Open1.8900
Bid0.0000 x 3000
Ask0.0000 x 2200
Day's Range1.5800 - 2.0000
52 Week Range0.5300 - 5.5200
Volume4,759,162
Avg. Volume4,216,191
Market Cap22.451M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMay 13, 2020 - May 17, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.00
  • AIkido Pharma Inc. Provides Update on Timing of Record Date and Anticipated Distribution Date for Dividend Distribution
    PR Newswire

    AIkido Pharma Inc. Provides Update on Timing of Record Date and Anticipated Distribution Date for Dividend Distribution

    AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the record date and distribution date to our stockholders of shares of Hoth Therapeutics, Inc. ("Hoth") will be deferred because of the requirement that the shares be registered prior to distribution. AIkido will provide a record date and distribution date for the distribution of the shares promptly once the registration statement is declared effective and will issue an update to shareholders in two weeks on the status of this matter.

  • AIkido Issues Shareholder Update on COVID-19, Dividend, And Path Forward
    PR Newswire

    AIkido Issues Shareholder Update on COVID-19, Dividend, And Path Forward

    AIkido Pharma Incorporated (Nasdaq: AIKI) today provided an update onto shareholders as follows:

  • AIKido Pharma Inc. Adopts Plan to Preserve Valuable Tax Assets
    PR Newswire

    AIKido Pharma Inc. Adopts Plan to Preserve Valuable Tax Assets

    AIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company") today announced that its Board of Directors (the "Board") has acted to preserve and protect the Company's valuable income tax net operating loss carryforwards ("NOLs") by adopting a stockholder rights plan in the form of a Section 382 Rights Agreement, dated as of March 23, 2020, by and between the Company and VStock Transfer LLC (the "Stockholder Rights Plan").

  • Shareholder Update from AIkido Pharma Incorporated on Coronavirus Option
    PR Newswire

    Shareholder Update from AIkido Pharma Incorporated on Coronavirus Option

    AIkido Pharma Incorporated (Nasdaq: AIKI) today provided an update on the recently announced Coronavirus technology optioned by the Company.

  • How Should Investors Feel About Spherix Incorporated's (NASDAQ:SPEX) CEO Pay?
    Simply Wall St.

    How Should Investors Feel About Spherix Incorporated's (NASDAQ:SPEX) CEO Pay?

    Anthony Hayes has been the CEO of Spherix Incorporated (NASDAQ:SPEX) since 2013. This analysis aims first to contrast...

  • Spherix Announces Closing of $5.75 Million Registered Direct Offering Priced At-the-Market
    PR Newswire

    Spherix Announces Closing of $5.75 Million Registered Direct Offering Priced At-the-Market

    Spherix Incorporated (SPEX) ("Spherix" or the "Company"), a technology development company committed to the fostering of innovative ideas, announced today the closing of its previously announced registered direct offering with several institutional investors of 2,090,909 shares of its common stock at a purchase price of $2.75 per share, priced at-the-market under Nasdaq rules. The gross proceeds to the Company from the offering totaled approximately $5.75 million, before deducting placement agent fees and offering expenses.

  • Shareholder Update on Treatment for Coronavirus Optioned by Spherix
    PR Newswire

    Shareholder Update on Treatment for Coronavirus Optioned by Spherix

    Spherix Incorporated (Nasdaq: SPEX) today provided an update on the recently announced treatment for Coronavirus technology optioned by the Company.

  • Spherix Announces $5.75 Million Registered Direct Offering Priced At-the-Market
    PR Newswire

    Spherix Announces $5.75 Million Registered Direct Offering Priced At-the-Market

    Spherix Incorporated (SPEX) ("Spherix" or the "Company"), a technology development company committed to the fostering of innovative ideas, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 2,090,909 shares of Spherix's common stock, at a purchase price of $2.75 per share, in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about March 11, 2020, subject to the satisfaction of customary closing conditions.

  • Benzinga

    Benzinga Pro's Top 5 Stocks To Watch For Mon., Mar. 9, 2020: XOM, GLD, BA, TSLA, SPEX

    Benzinga Pro's Stocks To Watch For Monday * ExxonMobil (XOM) \- Shares were down nearly 14% as the price of crude oil fell more than $9/barrel. Saudi officials decided to instigate a price war by cutting production over the weekend. Crude oil last traded around $32/barrel. * SPDR Gold ETF (GLD) \- This ETF was up about 0.3% in opposition to the move in oil. Gold also benefited amid reports the number of coronavirus cases confirmed outside China nearly tripled since last week. * Boeing (BA) \- The stock was down about 9% following a report the FAA may require the company to fix electrical wire issues before the 737 MAX can return to flight. * Tesla (TSLA) \- A weekend article from the FT suggested notable investor James Anderson, head of global equities for Baillie Gifford (Tesla's largest shareholder), said he was now "more comfortable" with the company following a recent management shuffle. Anderson called the appointment of Robyn Denholm, an independent board member since 2014, a "decisive move." * Spherix (SPEX) \- A new coronavirus play as of Friday, shares continued higher Monday morning. After closing up 131% on Friday, shares were up another 60% Monday morning. On Friday, the company announced the execution of exclusive option deal with University of Maryland for "Methods of Treating Coronavirus Infection" patent.See more from Benzinga * Benzinga Pro's Top 5 Stocks To Watch For Tues., Feb. 18, 2020: AAPL, WMT, TSLA, FLR, SPWR * Benzinga Pro's Top 5 Stocks To Watch For Fri., Feb. 14, 2020: TSLA, ROKU, CRON, YELP, AMD * Benzinga Pro's Top 5 Stocks To Watch For Thurs., Feb. 13, 2020: FXI, TSLA, BABA, NIO, CAT(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • MarketWatch

    Spherix stock soars after option executed for technology in patent for methods to treat coronavirus infection

    Shares of Spherix Inc. soared 21% in active morning trading Friday, after the biotechnology company said it executed an exclusive option agreement with the University of Maryland, Baltimore for the technology in the patent for "Methods of Treating Coronavirus Infection." Trading volume swelled to 2.2 million shares, already more than the full-day average of 1.2 million shares. The company said the invention was made with support awarded by the National Institutes of Health, which has certain rights in the invention. Under terms of the option, Spherix said it has until the end of May to execute a license agreement for commercial development. The stock has lost 23% over the past three months, while the iShares Nasdaq Biotechnology ETF has slipped 2.5% and the S&P 500 has shed 6.9%.

  • Treatment for Coronavirus Optioned by Spherix
    PR Newswire

    Treatment for Coronavirus Optioned by Spherix

    Spherix Incorporated (Nasdaq: SPEX) today announced it has executed an exclusive option agreement ("Option") with the University of Maryland, Baltimore (UMB) for the technology set forth in Patent number 10,434,116 "Methods of Treating Coronavirus Infection." The present invention provides methods for treating a coronavirus infection.

  • Spherix Incorporated Changing Name to AIkido Pharma Inc. to Reflect Increased Focus on Artificial Intelligence and Machine Learning in Drug Development
    PR Newswire

    Spherix Incorporated Changing Name to AIkido Pharma Inc. to Reflect Increased Focus on Artificial Intelligence and Machine Learning in Drug Development

    Spherix Incorporated (Nasdaq: SPEX) ("Spherix" or the "Company") today announced that on March 13, 2020, the Company will officially change its name to AIkido Pharma Inc. ("AIkido"). Effective at the start of trading on March 13, 2020, the Company's shares will trade on the Nasdaq Capital Market under the new name and the new stock symbol will be "AIKI". The name change reflects the Company's increased commitment to the use of artificial intelligence and machine learning in the drug development space.

  • Spherix Moves Dividend Record Date to Friday, March 6, 2020
    PR Newswire

    Spherix Moves Dividend Record Date to Friday, March 6, 2020

    Spherix Incorporated (Nasdaq: SPEX) announced that, in light of the expected closing of its public offering tomorrow, March 5, 2020, the record date with respect to the Hoth dividend has been moved to Friday, March 6, 2020, so that its new shareholders may participate in the Hoth dividend.

  • Spherix Executes Machine Learning Scientific Research Agreement
    PR Newswire

    Spherix Executes Machine Learning Scientific Research Agreement

    Spherix Incorporated (Nasdaq: SPEX) today announced it has executed a Scientific Research Agreement with The University of Texas Southwestern Medical Center with the goal of using machine learning to find genetic markers in people that indicate an increased risk of developing pancreatic cancer.

  • Spherix Announces Pricing of $7.5 Million Public Offering
    PR Newswire

    Spherix Announces Pricing of $7.5 Million Public Offering

    Spherix Incorporated (SPEX) ("Spherix" or the "Company"), a technology development company committed to the fostering of innovative ideas, today announced that it has priced a public offering of an aggregate of 7,142,858 shares of common stock (or common stock equivalents) of the Company and warrants to purchase up to 7,142,858 shares of common stock. Each share of common stock (or common stock equivalent) is being sold together with one warrant to purchase one share of common stock, at a public offering price of $1.05 per share and accompanying warrant. The shares of common stock (or common stock equivalents) and the accompanying warrants are being sold together in this offering, but will be issued separately and will be immediately separable upon issuance. The warrants are exercisable immediately and expire five years from the date of issuance. Each warrant has an exercise price of $1.05.

  • Spherix Attends Artificial Intelligence and Machine Learning Pharmaceutical Development Conference
    PR Newswire

    Spherix Attends Artificial Intelligence and Machine Learning Pharmaceutical Development Conference

    Spherix Incorporated (Nasdaq: SPEX) today announced its attendance at the AI & ML Drug Discovery Summit. The AI-ML in Drug Development Summit is the only conference to bring together industry leaders, technology experts and academics focused on augmenting the R&D; processes through the use of Artificial Intelligence and Machine Learning. The event, scheduled for February 24-26, 2020 at the DoubleTree by Hilton Hotel San Diego - Mission Valley, brings together industry leaders and academics who are developing and implementing technological solutions for some of pharma's greatest problems.

  • Spherix Announces a Special Dividend Distribution
    PR Newswire

    Spherix Announces a Special Dividend Distribution

    Spherix Incorporated (Nasdaq: SPEX) today announced that on February 21, 2020, a special committee of the Board of Directors of Spherix Incorporated ("Spherix") approved a distribution to Spherix stockholders of 70,000 shares of Hoth Therapeutics, Inc. ("Hoth") held by Spherix.

  • Spherix Issues Letter to Shareholders
    PR Newswire

    Spherix Issues Letter to Shareholders

    Spherix Incorporated (NASDAQ: SPEX), a technology development company committed to the fostering of innovative ideas, today issued a letter to shareholders:

  • Spherix Launches Newly Redesigned Website
    PR Newswire

    Spherix Launches Newly Redesigned Website

    Spherix Incorporated (Nasdaq: SPEX) today announced that it has redesigned the company's website (www.spherix.com) to illuminate the overall digital transformation and recently acquired anti-cancer therapeutics. The new digital platform will emphasize on technology acquired from world renowned institutions such as The University of Texas and Wake Forest University. Our diverse portfolio of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL). Treatments such as the DHA-dFdC identified by The University of Texas, has shown positive results in preclinical studies, inhibiting pancreatic tumor growth in clinically relevant transgenic models. In addition, Wake Forest University has provided a method of treatment for (AML) and (ALL) with the drug KPC-34. The launch of our redesigned website will reflect Spherix ongoing commitment to research in biotechnology development and oncological treatment.

  • Spherix Announces the Closing of CBM BioPharma Transaction
    PR Newswire

    Spherix Announces the Closing of CBM BioPharma Transaction

    Spherix Incorporated (Nasdaq: SPEX) today announced that it has closed the CBM BioPharma, Inc. transaction and is working to develop these cancer drugs.

  • Spherix Notes Additional Patent Coverage Granted
    PR Newswire

    Spherix Notes Additional Patent Coverage Granted

    Spherix Incorporated (Nasdaq: SPEX) announced today that additional patent coverage has been granted by the United States Patent & Trademark Office to the patent portfolio being acquired by Spherix, in the field of pancreatic cancer.

  • Spherix Issues Update to Shareholders
    PR Newswire

    Spherix Issues Update to Shareholders

    NEW YORK, Oct. 21, 2019 /PRNewswire/ -- Spherix Incorporated (SPEX) President and CEO, Anthony Hayes, today released a letter to shareholders outlining the Company's plans for its previously disclosed dividend distribution. As we accelerate our transformation into an innovative biotech company, I believe this is the optimal time to provide our shareholders with a detailed update.  I am excited at the potential for Spherix and believe we have put several important pieces in place to drive future success. First, October 21, 2019 is the record date for our dividend distribution.  If you are a shareholder of record at 5 p.m. Eastern Standard on that date, you will receive one share of Hoth Therapeutics, Inc common stock for every 29 shares of Spherix common stock you own.  The distribution of the Hoth shares is currently anticipated to occur on or about October 28, 2019, subject to effectiveness of the registration statement for such shares.

  • Spherix Highlights ValuEngine Upgrade to 'Buy' Rating
    PR Newswire

    Spherix Highlights ValuEngine Upgrade to 'Buy' Rating

    NEW YORK , Oct. 17, 2019 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) today announced that its stock has been upgraded to a "buy" rating from a "hold" rating in a research note ...

  • Emerging Markets Report: In the Money
    GlobeNewswire

    Emerging Markets Report: In the Money

    It is not often in the pages of the Emerging Markets Report do we get the opportunity to tell our readers that a Company is giving back roughly $425,000* worth of value to its shareholders. Every Spherix stockholder will be entitled to receive one share of Hoth common stock for every twenty-nine shares of Spherix common stock held as of 5 p.m. Eastern Time on October 21, 2019. Extrapolating from that model, ten thousand shares of Spherix at a cost basis of $16,900 earns the owner 344 Hoth shares worth $1,482 on paper.

  • Consulting for the Results: First Chinese Consulting Firm Kmind Presents Case Study at NACRA 2019
    PR Newswire

    Consulting for the Results: First Chinese Consulting Firm Kmind Presents Case Study at NACRA 2019

    PHOENIX, Oct. 15, 2019 /PRNewswire/ -- Kmind Consulting("Kmind"), China's benchmark competitive strategy consulting firm, was invited to present "Consulting for Results: An Experiment of Kingmind on companies in China", providing a unique insight on international business for the consulting industry. The invitation marks the first time a Chinese consulting company has been invited to present at the North American Case Research Association ("NACRA") in its 61-year history.